These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 37777684)
1. Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial. Bonvalot S; Cozic N; Le Cesne A; Blay JY; Penel N; Fau M; Chevreau C; Anract P; Waast D; Laurence V; Watson S; Duffaud F; Gouin F; Taieb S; Kind M; Lam L Ann Surg Oncol; 2023 Dec; 30(13):8653-8659. PubMed ID: 37777684 [TBL] [Abstract][Full Text] [Related]
2. A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis. Colombo C; Fiore M; Grignani G; Tolomeo F; Merlini A; Palassini E; Collini P; Stacchiotti S; Casali PG; Perrone F; Mariani L; Gronchi A Clin Cancer Res; 2022 Sep; 28(18):4027-4032. PubMed ID: 35247923 [TBL] [Abstract][Full Text] [Related]
3. Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention. van Broekhoven DL; Grünhagenl DJ; van Dalen T; van Coevorden F; Bonenkamp HJ; Been LB; Bemelmans MH; Dijkstra SD; Colombo C; Gronchi A; Verhoef C BMC Cancer; 2016 Aug; 16(1):686. PubMed ID: 27565718 [TBL] [Abstract][Full Text] [Related]
4. Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance. van Houdt WJ; Husson O; Patel A; Jones RL; Smith MJF; Miah AB; Messiou C; Moskovic E; Al-Muderis O; Benson C; Zaidi S; Dunlop A; Strauss DC; Hayes AJ; van der Graaf WTA Ann Surg Oncol; 2019 Dec; 26(13):4699-4706. PubMed ID: 31531797 [TBL] [Abstract][Full Text] [Related]
5. Factors Associated with Disease Stabilization of Desmoid-Type Fibromatosis. Kim Y; Rosario MS; Cho HS; Han I Clin Orthop Surg; 2020 Mar; 12(1):113-119. PubMed ID: 32117547 [TBL] [Abstract][Full Text] [Related]
6. Surgical excision versus observation as initial management of desmoid tumors: A population based study. Turner B; Alghamdi M; Henning JW; Kurien E; Morris D; Bouchard-Fortier A; Schiller D; Puloski S; Monument M; Itani D; Mack LA Eur J Surg Oncol; 2019 Apr; 45(4):699-703. PubMed ID: 30420189 [TBL] [Abstract][Full Text] [Related]
7. MR-guided focused ultrasound therapy of extra-abdominal desmoid tumors: a multicenter retrospective study of 105 patients. Düx DM; Baal JD; Bitton R; Chen J; Brunsing RL; Sheth VR; Rosenberg J; Kim K; Ozhinsky E; Avedian R; Ganjoo K; Bucknor M; Dobrotwir A; Ghanouni P Eur Radiol; 2024 Feb; 34(2):1137-1145. PubMed ID: 37615768 [TBL] [Abstract][Full Text] [Related]
8. A Nationwide Prospective Clinical Trial on Active Surveillance in Patients With Non-intraabdominal Desmoid-type Fibromatosis: The GRAFITI Trial. Schut AW; Timbergen MJM; van Broekhoven DLM; van Dalen T; van Houdt WJ; Bonenkamp JJ; Sleijfer S; Grunhagen DJ; Verhoef C Ann Surg; 2023 Apr; 277(4):689-696. PubMed ID: 35166264 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study. Zheng C; Fang J; Wang Y; Zhou Y; Tu C; Min L J Cancer Res Clin Oncol; 2021 Jul; 147(7):2127-2135. PubMed ID: 33452581 [TBL] [Abstract][Full Text] [Related]
10. What is the best front-line approach in patients with desmoid fibromatosis? - A retrospective analysis from a reference center. Sobczuk P; Agnieszczak IM; Grycuk W; Czarnecka AM; Świtaj T; Koseła-Paterczyk H; Morysiński T; Zdzienicki M; Rutkowski P Eur J Surg Oncol; 2021 Oct; 47(10):2602-2608. PubMed ID: 33994241 [TBL] [Abstract][Full Text] [Related]
12. The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution. Zheng C; Zhou Y; Wang Y; Luo Y; Tu C; Min L Drug Des Devel Ther; 2020; 14():3941-3950. PubMed ID: 33061299 [TBL] [Abstract][Full Text] [Related]
14. Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group. Crombé A; Kind M; Ray-Coquard I; Isambert N; Chevreau C; André T; Lebbe C; Cesne AL; Bompas E; Piperno-Neumann S; Saada E; Bouhamama A; Blay JY; Italiano A; AJR Am J Roentgenol; 2020 Dec; 215(6):1539-1548. PubMed ID: 32991215 [No Abstract] [Full Text] [Related]
15. Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis. Zanchetta E; Ciniselli CM; Bardelli A; Colombo C; Stacchiotti S; Baldi GG; Provenzano S; Bertulli R; Bini F; Casale A; Greco FG; Ferrari A; Verderio P; Fiore M; Gronchi A; Casali PG; Morosi C; Palassini E Cancer Med; 2021 Jul; 10(13):4356-4365. PubMed ID: 34102009 [TBL] [Abstract][Full Text] [Related]
16. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998). Keus RB; Nout RA; Blay JY; de Jong JM; Hennig I; Saran F; Hartmann JT; Sunyach MP; Gwyther SJ; Ouali M; Kirkpatrick A; Poortmans PM; Hogendoorn PCW; van der Graaf WTA Ann Oncol; 2013 Oct; 24(10):2672-2676. PubMed ID: 23868907 [TBL] [Abstract][Full Text] [Related]
17. Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI. Ingley KM; Burtenshaw SM; Theobalds NC; White LM; Blackstein ME; Gladdy RA; Thipphavong S; Gupta AA Cancer Med; 2019 Sep; 8(11):5047-5057. PubMed ID: 31301110 [TBL] [Abstract][Full Text] [Related]
18. Breast desmoid tumor management in France: toward a new strategy. Duazo-Cassin L; Le Guellec S; Lusque A; Chantalat E; Laé M; Terrier P; Coindre JM; Boulet B; Le Boulc'h M; Gangloff D; Meresse T; Chaput B; Al Ali A; Rimareix F; Bonvalot S; Vaysse C Breast Cancer Res Treat; 2019 Jul; 176(2):329-335. PubMed ID: 31016642 [TBL] [Abstract][Full Text] [Related]
19. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Colombo C; Miceli R; Le Péchoux C; Palassini E; Honoré C; Stacchiotti S; Mir O; Casali PG; Dômont J; Fiore M; Le Cesne A; Gronchi A; Bonvalot S Eur J Cancer; 2015 Jan; 51(2):186-92. PubMed ID: 25500145 [TBL] [Abstract][Full Text] [Related]
20. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Kasper B; Gruenwald V; Reichardt P; Bauer S; Rauch G; Limprecht R; Sommer M; Dimitrakopoulou-Strauss A; Pilz L; Haller F; Hohenberger P Eur J Cancer; 2017 May; 76():60-67. PubMed ID: 28282612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]